Diffuse Large B Cell Lymphoma Clinical Trials in Louisville, Kentucky

5 studies are recruiting for diffuse large b cell lymphoma in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

   The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Conf…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

   Locations

   135 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05139017 on ClinicalTrials.gov

2. Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

   Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.

   Stage

   Not phased

   Ages

   10 and older

   Site

   Norton Healthcare Cancer Center, Louisville, Kentucky

   Locations

   6 in total

   Run by

   Leuko Labs, Inc.

   See if you can join NCT06323447 on ClinicalTrials.gov

3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

   The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163), Louisville, Kentucky

   Locations

   285 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06717347 on ClinicalTrials.gov

4. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

   This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky

   Locations

   95 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05633615 on ClinicalTrials.gov

5. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute Pavilion, Louisville, Kentucky

   Locations

   114 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov